Cargando…
Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents
IMPORTANCE: Cytokine signaling, including tumor necrosis factor (TNF) and interleukin (IL)-6, through the Janus-kinase (JAK)–signal transducer and activator of transcription pathway, was hypothesized to attenuate the risk of Alzheimer disease and related dementia (ADRD) in the Drug Repurposing for E...
Autores principales: | Desai, Rishi J., Varma, Vijay R., Gerhard, Tobias, Segal, Jodi, Mahesri, Mufaddal, Chin, Kristyn, Horton, Daniel B., Kim, Seoyoung C., Schneeweiss, Sebastian, Thambisetty, Madhav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994126/ https://www.ncbi.nlm.nih.gov/pubmed/35394510 http://dx.doi.org/10.1001/jamanetworkopen.2022.6567 |
Ejemplares similares
-
Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020) -
Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease
por: Varma, Vijay R., et al.
Publicado: (2022) -
Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
por: Jin, Yinzhu, et al.
Publicado: (2023) -
Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
por: Jin, Yinzhu, et al.
Publicado: (2017) -
Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drugs
por: Pawar, Ajinkya, et al.
Publicado: (2021)